ClinicalTrials.gg
RecruitingNCT06217120COL-Micro-HFUpdated Nov 10, 2026

Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

A Phase 2 interventional study of Colchicine and Placebo in Heart Failure With Preserved Ejection Fraction and Microvascular Coronary Artery Disease, sponsored by Montreal Heart Institute. Recruiting at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Montreal Heart Institute · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now RecruitingStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies testing colchicine in Inflammation — 15 open to participants now, 18 under way, 8 of them phase 3. Colchicine · Inflammation.

Planned enrollment
26th of 35
64 · median 150
Started
2026
with 4 others
Phase 2
11 of 35
4 open now
Primary completion
2027-04
later than 7 of 17 live
Registered
25th of 35
by date
Lead sponsor
2 of 35
Montreal Heart Institute

Among the 35 studies testing colchicine in Inflammation, this one is the 26th largest by planned enrollment, is one of 5 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 7 of the 17 other live ones, and was the 25th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

15 of the 35 studies testing colchicine in Inflammation are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing colchicine in Inflammation, or all of them as a file.
02

Study summary

This study will evaluate the impact of colchicine on the change in myocardial flow reserve (MFR), a marker for coronary microvascular dysfunction (CMD), compared to a matched placebo in patients with heart failure and ejection fraction above 40% (including patients with improved EF).

Read the detailed description

This will be a pilot mechanistic study. Patients will be randomly assigned in a 1:1 ratio to receive colchicine 0.6 milligram (mg) daily or a matched placebo. The assessment of the primary endpoint will occur at 6 months after randomization.

The study aims to test the impact of reducing inflammation using a pharmacological strategy to reverse CMD in patients with HF and EF above 40%. In a randomized study, we will test the impact of colchicine on the change in myocardial flow reserve (MFR), a marker for CMD, compared to placebo. We will assess CMD using dipyridamole-based positron emission tomography (PET).

The primary objective will be to compare the change from baseline to 6 months in MFR according to therapy.

The primary Endpoint will be the change from baseline to 6 months in MFR, a marker of CMD assessed using PET-imaging.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Microvascular Coronary Artery Disease

Browse trials for

Keywords

  • Heart Failure with Preserved Ejection Fraction
  • Microvascular Coronary Artery Disease
  • Inflammation
  • Colchicine
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects ≥ 40 years of age,
  2. Chronic symptomatic HF and (LVEF) > 40% within 12 months prior to screening visit (regardless of the imaging modality) and one of the following abnormalities:

2a. HF requiring hospitalization and IV diuretics within 12 months of study entry, or 2b. NTproBNP > 150pg/ml in sinus rhythm or NTproBNP > 450pg/ml in chronic atrial fibrillation, 3. The presence of coronary microvascular dysfunction (CMD) at baseline assessed using dipyridamole-based PET imaging and defined as myocardial functional reserve (MFR) \< 2.0, 4. Symptoms of HF requiring current treatment with loop diuretics for ≥ 30 days, 5. functional class II to (ambulatory) IV, 6. High-sensitivity C-reactive protein (hs-CRP) > 5mg/L at baseline, 7. Subjects with the capacity to provide .

Exclusion criteria

Exclusion Criteria:

  1. Patients with a diagnosis of infiltrative cardiomyopathy,
  2. Presence of primary severe valvular heart disease (functional MR/TR are not excluded),
  3. Presence of active infection within the 3 months prior to enrollment needing antibiotics,
  4. Acute decompensated HF, acute coronary syndrome (including MI), cardiac surgery, other major cardiovascular surgery, or urgent PCI within the 3 months prior to enrollment,
  5. Known or clinically judged significant (i.e., angina with CCS class > 2/4) epicardial coronary artery disease (CAD) that has not been revascularized (revascularized CAD is defined by a history of myocardial infarction, percutaneous intervention, or coronary artery bypass grafting),
  6. History of to colchicine,
  7. Evidence of hepatic disease as determined by any 1 of the following: (AST) or SGPT (ALT) values exceeding 3× the at enrollment; or patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease,
  8. Patients with at most moderate renal impairment defined as an \< 59 ml/min/1.73 m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at enrollment,
  9. Subject with inflammatory bowel disease (Crohn's disease or ulcerative colitis) or patient with chronic diarrhea,
  10. Patient with pre-existent progressive neuromuscular disease,
  11. Patient currently taking colchicine for other indications (Familial Mediterranean Fever, gout or post MI). There is no required for patients who have been treated with colchicine and stopped treatment prior to enrolment,
  12. Patients under long-term systemic medication or any chronic use of anti- inflammatory medication (including Non-steroidal Anti-inflammatory Drugs, NSAIDS),
  13. to dipyridamole use (PET-imaging): Patients with bronchospastic lung disease with ongoing wheezing; Acute myocardial infarction or unstable angina in the past 48h; Uncontrolled hypertension (systolic pressure of over 200 mmHg or a diastolic pressure of over 110 mmHg); Symptomatic hypotension; Untreated second- or third-degree atrioventricular block; Known hypersensitivity to dipyridamole; Caffeine intake in the previous 12 hours
  14. Contra-indications to aminophylline use (PET-imaging): epilepsy, peptic ulcer (active) and hypersensitivity to aminophylline, theophylline, ethylenediamine, or any component of the formulation
  15. Positive pregnancy test result at the screening visit, and females of who do not agree to use adequate method of for the duration of the study; acceptable means of birth control include: implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner,
  16. History or presence of any other disease with a of \<1 year,
  17. Patient considered by the investigator, for any reason, to be an unsuitable candidate for the study,
  18. Drug-drug interaction (competitive inhibition of and P-gp): Patients treated with amiodarone, dronedarone, quinidine, propafenone, diltiazem, azithromycin or high-intensity statin therapy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    COLCHICINE

    Drug: Colchicine

  • Placebo comparator
    PLACEBO

    Drug: Placebo

Interventions

  • Colchicine 0.6 mg once daily

  • DrugPlacebo

    Placebo once daily

06

What researchers measure

Primary outcomes

  1. Change in myocardial flow reserve (MFR) between baseline and six months

    The primary outcome measure will be the change from baseline to 6 months in MRF, a marker of coronary microvascular dysfunction (CMD), according to therapy (colchicine vs. placebo). Assessment of MFR will be based on 82-Rubidium Positron emission tomography (82Rb-PET)-myocardial perfusion imaging, performed at baseline and 6-month follow up.

    Time frame: Baseline and 6 months

Other outcomes

  1. Change in circulating levels of NT-proBNP and hs-CRP between baseline and six months

    The secondary outcome measure will be the change in circulating levels of NT-proBNP and hs-CRP from baseline to 6 months. NT-proBNP and hs-CRP will be assessed locally as part of the patients' usual follow-up.

    Time frame: Baseline and 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Authors/Task Force Members:; McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 Jan;24(1):4-131. doi: 10.1002/ejhf.2333. PubMed 35083827 ↗
  • Marinescu MA, Loffler AI, Ouellette M, Smith L, Kramer CM, Bourque JM. Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging. 2015 Feb;8(2):210-20. doi: 10.1016/j.jcmg.2014.12.008. PubMed 25677893 ↗
  • Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, Sadowski Z, Golba KS, Prior DL, Rouleau JL, Bonow RO. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006 Sep 12;114(11):1202-13. doi: 10.1161/CIRCULATIONAHA.106.623199. No abstract available. PubMed 16966596 ↗
  • Yong J, Tian J, Yang X, Xing H, He Y, Song X. Effects of Oral Drugs on Coronary Microvascular Function in Patients Without Significant Stenosis of Epicardial Coronary Arteries: A Systematic Review and Meta-Analysis of Coronary Flow Reserve. Front Cardiovasc Med. 2020 Oct 30;7:580419. doi: 10.3389/fcvm.2020.580419. eCollection 2020. PubMed 33195465 ↗
  • Yang JH, Obokata M, Reddy YNV, Redfield MM, Lerman A, Borlaug BA. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2020 Mar;22(3):432-441. doi: 10.1002/ejhf.1671. Epub 2019 Dec 15. PubMed 31840366 ↗
  • Vaccarino V, Khan D, Votaw J, Faber T, Veledar E, Jones DP, Goldberg J, Raggi P, Quyyumi AA, Bremner JD. Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins. J Am Coll Cardiol. 2011 Mar 15;57(11):1271-9. doi: 10.1016/j.jacc.2010.09.074. PubMed 21392641 ↗
  • Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Kober L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 Aug 6;74(5):601-612. doi: 10.1016/j.jacc.2019.05.052. PubMed 31370950 ↗
  • Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16. PubMed 31733140 ↗
  • Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, Hainer J, Bibbo CF, Dorbala S, Blankstein R, Di Carli MF. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018 Mar 7;39(10):840-849. doi: 10.1093/eurheartj/ehx721. PubMed 29293969 ↗
  • Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, Dorbala S, Blankstein R, Di Carli MF. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015 Jan 6;131(1):19-27. doi: 10.1161/CIRCULATIONAHA.114.011939. Epub 2014 Nov 16. PubMed 25400060 ↗
  • Taqueti VR, Everett BM, Murthy VL, Gaber M, Foster CR, Hainer J, Blankstein R, Dorbala S, Di Carli MF. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. Circulation. 2015 Feb 10;131(6):528-35. doi: 10.1161/CIRCULATIONAHA.114.009716. Epub 2014 Dec 5. PubMed 25480813 ↗
  • Suhrs HE, Schroder J, Bove KB, Mygind ND, Frestad D, Michelsen MM, Lange T, Gustafsson I, Kastrup J, Prescott E. Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked? PLoS One. 2020 Jul 16;15(7):e0236035. doi: 10.1371/journal.pone.0236035. eCollection 2020. PubMed 32673354 ↗
  • Shaw LJ, Berman DS, Picard MH, Friedrich MG, Kwong RY, Stone GW, Senior R, Min JK, Hachamovitch R, Scherrer-Crosbie M, Mieres JH, Marwick TH, Phillips LM, Chaudhry FA, Pellikka PA, Slomka P, Arai AE, Iskandrian AE, Bateman TM, Heller GV, Miller TD, Nagel E, Goyal A, Borges-Neto S, Boden WE, Reynolds HR, Hochman JS, Maron DJ, Douglas PS; National Institutes of Health/National Heart, Lung, and Blood Institute-Sponsored ISCHEMIA Trial Investigators. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging. 2014 Jun;7(6):593-604. doi: 10.1016/j.jcmg.2013.10.021. PubMed 24925328 ↗
  • Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, Beussink-Nelson L, Ljung Faxen U, Fermer ML, Broberg MA, Gan LM, Lund LH. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018 Oct 1;39(37):3439-3450. doi: 10.1093/eurheartj/ehy531. PubMed 30165580 ↗
  • Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collins S, Deo RC, Gladwin MT, Granzier H, Hummel SL, Kass DA, Redfield MM, Sam F, Wang TJ, Desvigne-Nickens P, Adhikari BB. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020 Mar 24;141(12):1001-1026. doi: 10.1161/CIRCULATIONAHA.119.041886. Epub 2020 Mar 23. PubMed 32202936 ↗
  • Schindler TH, Dilsizian V. Coronary Microvascular Dysfunction: Clinical Considerations and Noninvasive Diagnosis. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):140-155. doi: 10.1016/j.jcmg.2018.11.036. Epub 2019 Apr 12. PubMed 30982670 ↗
  • Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10. PubMed 31518657 ↗
  • Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E, Liew D, Imazio M, Cornel JH, Thompson PL, Nidorf M. Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. Am J Med. 2022 Jan;135(1):32-38. doi: 10.1016/j.amjmed.2021.07.025. Epub 2021 Aug 18. PubMed 34416165 ↗
  • Paulus WJ, Zile MR. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure With Preserved Ejection Fraction Paradigm Revisited. Circ Res. 2021 May 14;128(10):1451-1467. doi: 10.1161/CIRCRESAHA.121.318159. Epub 2021 May 13. PubMed 33983831 ↗
  • Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092. Epub 2013 May 15. PubMed 23684677 ↗
  • Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9. doi: 10.1056/NEJMoa052256. PubMed 16855265 ↗
  • Ong P, Athanasiadis A, Sechtem U. Pharmacotherapy for coronary microvascular dysfunction. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):65-71. doi: 10.1093/ehjcvp/pvu020. PubMed 27533969 ↗
  • Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020 Nov 5;383(19):1838-1847. doi: 10.1056/NEJMoa2021372. Epub 2020 Aug 31. PubMed 32865380 ↗
  • Murthy VL, Lee BC, Sitek A, Naya M, Moody J, Polavarapu V, Ficaro EP, Di Carli MF. Comparison and prognostic validation of multiple methods of quantification of myocardial blood flow with 82Rb PET. J Nucl Med. 2014 Dec;55(12):1952-8. doi: 10.2967/jnumed.114.145342. PubMed 25429160 ↗
  • Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, Cerqueira MD, deKemp RA, DePuey EG, Dilsizian V, Dorbala S, Ficaro EP, Garcia EV, Gewirtz H, Heller GV, Lewin HC, Malhotra S, Mann A, Ruddy TD, Schindler TH, Schwartz RG, Slomka PJ, Soman P, Di Carli MF; SNMMI Cardiovascular Council Board of Directors; ASNC Board of Directors. Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. J Nucl Med. 2018 Feb;59(2):273-293. doi: 10.2967/jnumed.117.201368. Epub 2017 Dec 14. No abstract available. PubMed 29242396 ↗
  • Murphy SP, Kakkar R, McCarthy CP, Januzzi JL Jr. Inflammation in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar 24;75(11):1324-1340. doi: 10.1016/j.jacc.2020.01.014. PubMed 32192660 ↗
  • Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep. 2002 Jun;4(3):252-6. doi: 10.1007/s11926-002-0073-2. PubMed 12010611 ↗
  • Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015 Feb 10;131(6):550-9. doi: 10.1161/CIRCULATIONAHA.114.009625. Epub 2014 Dec 31. PubMed 25552356 ↗
  • Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1765-74. doi: 10.1007/s00259-007-0478-2. Epub 2007 Jul 7. PubMed 17619189 ↗
  • Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002 Dec 10;106(24):3068-72. doi: 10.1161/01.cir.0000039105.49749.6f. PubMed 12473553 ↗
  • Lam CSP, Solomon SD. Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Jun 29;77(25):3217-3225. doi: 10.1016/j.jacc.2021.04.070. PubMed 34167646 ↗
  • Karatza E, Ismailos G, Karalis V. Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens. Xenobiotica. 2021 Jun;51(6):643-656. doi: 10.1080/00498254.2021.1909782. Epub 2021 Apr 12. PubMed 33845715 ↗
  • Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2817-27. doi: 10.1016/j.jacc.2014.03.034. Epub 2014 Apr 23. PubMed 24768876 ↗
  • Hage C, Svedlund S, Saraste A, Faxen UL, Benson L, Fermer ML, Gan LM, Shah SJ, Lam CSP, Lund LH. Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. J Card Fail. 2020 Nov;26(11):1016-1021. doi: 10.1016/j.cardfail.2020.08.010. Epub 2020 Aug 23. PubMed 32846205 ↗
  • Efseaff M, Klein R, Ziadi MC, Beanlands RS, deKemp RA. Short-term repeatability of resting myocardial blood flow measurements using rubidium-82 PET imaging. J Nucl Cardiol. 2012 Oct;19(5):997-1006. doi: 10.1007/s12350-012-9600-3. Epub 2012 Jul 24. PubMed 22826134 ↗
  • DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PLoS One. 2018 Aug 16;13(8):e0201836. doi: 10.1371/journal.pone.0201836. eCollection 2018. PubMed 30114262 ↗
  • Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG, Siasos G, Nicolas J, Arnott C, Patel S, Parsons M, Tardif JC, Kovacic JC, Dangas GD. Colchicine in Cardiovascular Disease: In-Depth Review. Circulation. 2022 Jan 4;145(1):61-78. doi: 10.1161/CIRCULATIONAHA.121.056171. Epub 2021 Dec 29. PubMed 34965168 ↗
  • Caliskan M, Erdogan D, Gullu H, Topcu S, Ciftci O, Yildirir A, Muderrisoglu H. Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow. Clin Cardiol. 2007 Sep;30(9):475-9. doi: 10.1002/clc.20140. PubMed 17803205 ↗
  • Buckley LF, Libby P. Colchicine's Role in Cardiovascular Disease Management. Arterioscler Thromb Vasc Biol. 2024 May;44(5):1031-1041. doi: 10.1161/ATVBAHA.124.319851. Epub 2024 Mar 21. PubMed 38511324 ↗
  • Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9. doi: 10.1056/NEJMoa051530. PubMed 16855266 ↗
  • Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. No abstract available. PubMed 29386200 ↗
  • Bateman TM, Heller GV, Beanlands R, Calnon DA, Case J, deKemp R, Gordon DePuey E, Di Carli M, Guler EC, Murthy VL, Rosenblatt J, Sher R, Slomka P, Ruddy TD. Practical guide for interpreting and reporting cardiac PET measurements of myocardial blood flow: an Information Statement from the American Society of Nuclear Cardiology, and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Cardiol. 2021 Apr;28(2):768-787. doi: 10.1007/s12350-021-02552-7. Epub 2021 Mar 30. No abstract available. PubMed 33786730 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Apr 2027, 5 months after the start.

Of 113 non-industry phase 2 interventional studies under Inflammation, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 5 months is below that.

Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Mar 2024 → Nov 2026, primary completion Oct 2025 → Apr 2027 and completion Mar 2026 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Jan 22, 2024
StartActual
Nov 6, 2026was Mar 2024
Primary completionEst.
Apr 2027was Oct 2025
CompletionEst.
May 2028was Mar 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added, 1 site removed
Show site
  • Centre de recherche du Centre hospitalier de l'Université de Montréal · Montreal, Canada
Show 1 removed
  • Montreal Heart Institute · Montréal, Canada
Nov 10, 2026
Start date
Mar 1, 2024→Nov 6, 2026 (actual)
Nov 10, 2026
Primary completion
Oct 1, 2025→Apr 2027
Nov 10, 2026
Study completion
Mar 1, 2026→May 2028
Nov 10, 2026
Enrollment
60→64
Nov 10, 2026
Eligibility
1 inclusion criterion edited, 1 added, 5 removed; 8 exclusion criteria edited, 4 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedChronic symptomatic HF and left ventricular ejection fraction (LVEF) > 40% within 12 months prior to the screening visit (regardless of the imaging modality) documented byand one of the following abnormalities:
  • RemovedHF requiring hospitalization and IV diuretics within 12 months of study entry, or
  • RemovedNTproBNP > or = 150pg/ml in sinus rhythm or NTproBNP > or = 450pg/ml in chronic atrial fibrillation,
  • RemovedNew York Heart Association Class, NYHA functional class II to (ambulatory) IV,
  • RemovedEvidence of pathological systemic inflammation: high C-reactive protein, hs-CRP levels (hs-CRP > or = 5mg/L),
  • RemovedSubjects with the capacity to provide informed consent.
  • Added2a. HF requiring hospitalization and IV diuretics within 12 months of study entry, or 2b. NTproBNP > 150pg/ml in sinus rhythm or NTproBNP > 450pg/ml in chronic atrial fibrillation, 3. The presence of coronary microvascular dysfunction (CMD) at baseline assessed using dipyridamole-based PET imaging and defined as myocardial functional reserve (MFR) < 2.0, 4. Symptoms of HF requiring current treatment with loop diuretics for ≥ 30 days, 5. NYHA functional class II to (ambulatory) IV, 6. High-sensitivity C-reactive protein (hs-CRP) > 5mg/L at baseline, 7. Subjects with the capacity to provide informed consent.
Exclusion criteria
  • EditedPresence of primary severe valvular heart disease (functional MR/TR are not excluded),
  • EditedPresence of active infection within the 3 months prior to enrollment needing antibiotics (excluding COVID (Coronavirus disease)-19),
  • EditedAcute decompensated HF, acute coronary syndrome (including MI), cardiac surgery, other major cardiovascular surgery, or urgent percutaneous coronary intervention (PCI) within the 3 months prior to enrollment,
  • EditedKnown or clinically judged significant (i.e., angina with CCS (Canadian Cardiovascular Society) class > 2/4) epicardial coronary artery disease (CAD) that has not been revascularized (revascularized CAD is defined by a history of myocardial infarction, percutaneous intervention, or coronary artery bypass grafting),
  • EditedEvidence of hepatic disease as determined by any 1 of the following: SGOT (AST) or SGPT (ALT) values exceeding 3× the upper limit of normal at enrollment; or patient with a history of cirrhosis, chronic active hepatitis, or severe hepatic disease,
  • EditedPatients with estimated glomerular filtration rate (at most moderate renal impairment defined as an eGFR) <30 59 ml/min/1.73 m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at enrollment,
  • EditedPatient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever, gout or goutpost MI). There is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment,
  • RemovedPatients under long-term steroid medication for a chronic condition,
  • RemovedContraindication to dipyridamole-containing medication, acute myocardial infarction or unstable angina in the past 48h,
  • AddedPatients under long-term systemic steroid medication or any chronic use of anti- inflammatory medication (including Non-steroidal Anti-inflammatory Drugs, NSAIDS),
  • AddedContra-indications to dipyridamole use (PET-imaging): Patients with bronchospastic lung disease with ongoing wheezing; Acute myocardial infarction or unstable angina in the past 48h; Uncontrolled hypertension (systolic pressure of over 200 mmHg or a diastolic pressure of over 110 mmHg); Symptomatic hypotension; Untreated second- or third-degree atrioventricular block; Known hypersensitivity to dipyridamole; Caffeine intake in the previous 12 hours
  • AddedContra-indications to aminophylline use (PET-imaging): epilepsy, peptic ulcer (active) and hypersensitivity to aminophylline, theophylline, ethylenediamine, or any component of the formulation
  • EditedPositive pregnancy test resultsresult at the screening visit, and females of childbearing potential who do not agree to use adequate methodsmethod of contraception for the duration of the study; acceptable means of birth control include: implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner,
  • AddedDrug-drug interaction (competitive inhibition of CYP3A4 and P-gp): Patients treated with amiodarone, dronedarone, quinidine, propafenone, diltiazem, azithromycin or high-intensity statin therapy.
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in coronarymyocardial flow reserve (CFRMFR) between baseline and six monthsTime frame: Baseline and 6 months
Nov 10, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • Addedother outcomeChange in circulating levels of NT-proBNP and hs-CRP between baseline and six monthsTime frame: Baseline and 6 months
Nov 10, 2026
Design
Removed Phase 3
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Centre de recherche du Centre hospitalier de l'Université de Montréal · Montreal, Canada
    Show 1 removed
    • Montreal Heart Institute · Montréal, Canada
    Start date Mar 1, 2024→Nov 6, 2026 (now actual)
    Primary completion Oct 1, 2025→Apr 2027
    Study completion Mar 1, 2026→May 2028
    Enrollment 60→64
    Eligibility 1 inclusion criterion edited, 1 added, 5 removed; 8 exclusion criteria edited, 4 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedChronic symptomatic HF and left ventricular ejection fraction (LVEF) > 40% within 12 months prior to the screening visit (regardless of the imaging modality) documented byand one of the following abnormalities:
    • RemovedHF requiring hospitalization and IV diuretics within 12 months of study entry, or
    • RemovedNTproBNP > or = 150pg/ml in sinus rhythm or NTproBNP > or = 450pg/ml in chronic atrial fibrillation,
    • RemovedNew York Heart Association Class, NYHA functional class II to (ambulatory) IV,
    • RemovedEvidence of pathological systemic inflammation: high C-reactive protein, hs-CRP levels (hs-CRP > or = 5mg/L),
    • RemovedSubjects with the capacity to provide informed consent.
    • Added2a. HF requiring hospitalization and IV diuretics within 12 months of study entry, or 2b. NTproBNP > 150pg/ml in sinus rhythm or NTproBNP > 450pg/ml in chronic atrial fibrillation, 3. The presence of coronary microvascular dysfunction (CMD) at baseline assessed using dipyridamole-based PET imaging and defined as myocardial functional reserve (MFR) < 2.0, 4. Symptoms of HF requiring current treatment with loop diuretics for ≥ 30 days, 5. NYHA functional class II to (ambulatory) IV, 6. High-sensitivity C-reactive protein (hs-CRP) > 5mg/L at baseline, 7. Subjects with the capacity to provide informed consent.
    Exclusion criteria
    • EditedPresence of primary severe valvular heart disease (functional MR/TR are not excluded),
    • EditedPresence of active infection within the 3 months prior to enrollment needing antibiotics (excluding COVID (Coronavirus disease)-19),
    • EditedAcute decompensated HF, acute coronary syndrome (including MI), cardiac surgery, other major cardiovascular surgery, or urgent percutaneous coronary intervention (PCI) within the 3 months prior to enrollment,
    • EditedKnown or clinically judged significant (i.e., angina with CCS (Canadian Cardiovascular Society) class > 2/4) epicardial coronary artery disease (CAD) that has not been revascularized (revascularized CAD is defined by a history of myocardial infarction, percutaneous intervention, or coronary artery bypass grafting),
    • EditedEvidence of hepatic disease as determined by any 1 of the following: SGOT (AST) or SGPT (ALT) values exceeding 3× the upper limit of normal at enrollment; or patient with a history of cirrhosis, chronic active hepatitis, or severe hepatic disease,
    • EditedPatients with estimated glomerular filtration rate (at most moderate renal impairment defined as an eGFR) <30 59 ml/min/1.73 m2 as calculated by the Modification in Diet in Renal Disease (MDRD) formula at enrollment,
    • EditedPatient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever, gout or goutpost MI). There is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment,
    • RemovedPatients under long-term steroid medication for a chronic condition,
    • RemovedContraindication to dipyridamole-containing medication, acute myocardial infarction or unstable angina in the past 48h,
    • AddedPatients under long-term systemic steroid medication or any chronic use of anti- inflammatory medication (including Non-steroidal Anti-inflammatory Drugs, NSAIDS),
    • AddedContra-indications to dipyridamole use (PET-imaging): Patients with bronchospastic lung disease with ongoing wheezing; Acute myocardial infarction or unstable angina in the past 48h; Uncontrolled hypertension (systolic pressure of over 200 mmHg or a diastolic pressure of over 110 mmHg); Symptomatic hypotension; Untreated second- or third-degree atrioventricular block; Known hypersensitivity to dipyridamole; Caffeine intake in the previous 12 hours
    • AddedContra-indications to aminophylline use (PET-imaging): epilepsy, peptic ulcer (active) and hypersensitivity to aminophylline, theophylline, ethylenediamine, or any component of the formulation
    • EditedPositive pregnancy test resultsresult at the screening visit, and females of childbearing potential who do not agree to use adequate methodsmethod of contraception for the duration of the study; acceptable means of birth control include: implantable contraceptives, injectable contraceptives, oral contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner,
    • AddedDrug-drug interaction (competitive inhibition of CYP3A4 and P-gp): Patients treated with amiodarone, dronedarone, quinidine, propafenone, diltiazem, azithromycin or high-intensity statin therapy.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in coronarymyocardial flow reserve (CFRMFR) between baseline and six monthsTime frame: Baseline and 6 months
    Secondary outcomes 1 added
    What changed in the outcomes
    • Addedother outcomeChange in circulating levels of NT-proBNP and hs-CRP between baseline and six monthsTime frame: Baseline and 6 months
    Design Removed Phase 3
    + 8 other changes: identifiers, verification date, responsible party, oversight details, description, arm descriptions, data sharing statement and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06217120
Collaborators
Heart and Stroke Foundation of Canada, Centre hospitalier de l'Université de Montréal (CHUM)
Responsible party
Nadia Bouabdallaoui (MD, PhD, Centre hospitalier de l'Université de Montréal (CHUM)) — Principal investigator
First posted
Jan 22, 2024
Start date
Nov 6, 2026
Primary completion
Apr 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion